Navigation Links
Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
Date:5/1/2008

nformation please contact:

Porter Novelli for Shire:

Lucia Lodato

Lucia.Lodato@porternovelli.com

212.601.8037

917.617.3058 (on site at the meeting)

Lauren Plate

Lauren.Plate@porternovelli.com

212.601.8188

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. For further information on Shire, please visit the Company's website: http://www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development including, but not limited to the successful development of JUVISTA(R) (Human TGF(beta)3) and veleglucerase alfa (GA-GCB); manufacturing and commerc
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
2. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
3. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
4. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
5. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
6. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
7. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
10. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
11. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 Valeant Pharmaceuticals International, ... has priced its previously announced public offering of common ... will issue 23,529,412 common shares at a price of ... $2.0 billion. The Company will file a final prospectus ... S-3 and will make a similar filing with the ...
(Date:6/18/2013)... , June 18, 2013 Royal Philips ... was named Overall Performance Leader in Imaging Equipment in ... Infrastructure report. Philips also received Best in KLAS and ... products: Ingenuity Core 128 Computed Tomography (CT), Ingenia ... PageWriter TC70 cardiograph. The annual Best in KLAS Awards: ...
(Date:6/18/2013)... 2013  Cataracts are the leading cause of blindness ... Ophthalmology, aging is the leading cause of eye diseases ... lens. 22 million Americans age 40 and older have ... age, that number will increase over 30 million.  In ... smart-phones and computers, the demographic of ages 40 plus ...
Breaking Medicine Technology:Valeant Pharmaceuticals Prices Public Offering Of Common Shares 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 4Philips Named 2013 Overall Performance Leader In Imaging Equipment By KLAS 2New Vision Hope For Millions Undergoing Cataract Surgery 2New Vision Hope For Millions Undergoing Cataract Surgery 3
... ViroPharma Incorporated (Nasdaq: VPHM ) today announced ... esterase inhibitor [human]) therapy at the 6th Annual C1 ... Food and Drug Administration in October 2008 for routine ... adolescents. In February 2009, ViroPharma was granted priority review ...
... 26 Ascenta Therapeutics announced today that eleven presentations ... an oral, pan-Bcl-2 inhibitor, in several major tumor types ... Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, in ... www.asco.org .(Logo: http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGO ...
Cached Medicine Technology:Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop 2Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop 3Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop 4Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop 5Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop 6Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop 7Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 2Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 3
(Date:6/19/2013)... of the genetic process that can lead to cervical ... for some women, and also raises a warning flag ... suggesting they could actually trigger the cancer they ... clearer picture of the chromosomal and genetic changes that ... chronic infection and, in less than 1 percent of ...
(Date:6/19/2013)... Casual, no-strings sexual encounters are increasingly common on ... than others to "hook up"? A new study ... Behavioral and Preventive Medicine, published online by the ... are certain factors and behaviors associated with sexual ... "Given the potential for negative emotional and physical ...
(Date:6/19/2013)... Japanese pharmaceutical companies, along with the Japanese government ... their commitment to bolster Japan,s contribution to global ... (GHIT Fund), at a press conference held as ... Conference on African Development (TICAD V). , Representatives ... Ministry of Health, Labour and Welfare, the Ministry ...
(Date:6/19/2013)... 19, 2013 DiscountFurnaceFilter.com, the number one solution ... the 5-2-1 Compressor Saver kit at an exceptional price. The ... aids the air conditioning unit during start up, saving wear ... compressor or unit burn out. , The 5-2-1 Compressor ... air conditioner uses less power to start and drastically reduces ...
(Date:6/19/2013)... At a Travel Services Member Conference, former owner ... has occurred over the last year since he gave up ... Services has added vendors, lowered prices of travel and grew ... up, even in the tough economy, and they've hired 25% ... Having been in the Travel Business and Timeshare Industry for ...
Breaking Medicine News(10 mins):Health News:Genetics of cervical cancer raise concern about antiviral therapy in some cases 2Health News:Why are some college students more likely to 'hook up'? 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 3Health News:Former Owner Eric Shuman Endorses New Owners and Changes Made in Last Year Since Shuman Sold Travel Services Center at Member Conference 2
... the pre-existent belief, of children who had received multiple ... other diseases, is a myth and nothing else. The ... JAMA. ,During the last 2 decades, more vaccinations ... become increasingly complex, according to background information in the ...
... More young people appear to be developing the most common ... increase in the cost and suffering //caused by the disease ... the sun, usually develop in older people who have spent ... and squamous cell carcinomas, cancers that are almost always curable ...
... Organ Act was passed in India, we have not made ... various reasons. //First and foremost has been lack of direction ... to living organ donation. , There has been a ... passed. Whenever there is a kidney scandal there is a ...
... Drug Digoxin or Digitalis, which comes from the foxglove plant, ... maintaining the rhythm of the heart and treat heart diseases. ... team of researchers from University of Wisconsin-Madison to make the ... neo (new)-glyco (sugar)-randomisation, which works by changing the sugars attached ...
... diets could be due to their high protein// content, ... help fight obesity., ,In a recent study researchers ... while maintaining carbohydrate intake decreases the appetite, leads to ... loss. However some are of the opinion that preventing ...
... factors. But according to the research finding published by the ... that calorie intake may not be a major factor in ... based on a 17-year study of almost 9,790 Americans, who ... a national study which was done from 1971 to 1975. ...
Cached Medicine News:Health News:Myth Of Childhood Vaccinations Linked To Increased Hospitalization Busted 2Health News:The Potential Of Cadaver Transplantation Programme In India 2Health News:The Potential Of Cadaver Transplantation Programme In India 3Health News:Finding The Key To Weight Loss! 2
... the Flavavirus group pf viruses. This virus ... Dengue fever are the sudden onset of ... limbs, lymphadenopathy,maculopapular rash and retrobulbar pain.,This test ... aid in the diagnosis of anti-Dengue IgM ...
... The Dengue virus belongs to the Flavavirus ... commonly throughout the tropics.,Symptoms of Dengue fever ... pain in the back and limbs, lymphadenopathy,maculopapular ... for professional use as an aid in ...
The IntraStent DoubleStrut Biliary Stent represents a completely new direction in stent design. The combination of parallel struts and unique cell geometry provide unparalleled performance....
For the rapid determination of human chorionic gonadotropin (hCG) in urine. The test strip is used to obtain a visual qualitative result....
Medicine Products: